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HyperaldosteronismAldosterone is 1 of the various hormones with detri-
mental functions for the failing heart, whose circu-
lating levels are elevated post-myocardial infarction
(MI) and in patients with chronic heart failure (HF) (1).
We have recently discovered that angiotensin II, acting
through its type 1 receptors (AT1Rs) in the adrenal cor-
tex, can elicit aldosterone synthesis and secretion
through both G protein– and b-arrestin1 (barr1)–depen-
dent signaling pathways, thereby exacerbating post-MI
HF (1,2). In addition, the prototypic angiotensin re-
ceptor blocker (ARB) drug losartan appears to be
ineffective at combating the adrenal barr1-dependent
hyperaldosteronism post-MI (2). Therefore, in the
present study, we investigated the potencies of
several other ARBs at suppression of adrenal barr1-
dependent post-MI hyperaldosteronism in vivo.
All methods have been described previously (2).
One- or 2-way analysis of variance models with the
Bonferroni test and/or Dunnett’s test, using SAS
version 8.2 software (SAS Institute, Cary, North Car-
olina), were used for statistical comparisons.
Treatment for 7 days with valsartan or candesartan
markedly reduced circulating aldosterone levels
(post-MI–associated hyperaldosteronism) in post-MI
rats overexpressing barr1 speciﬁcally in their adrenal
glands. However, irbesartan treatment for the same
time period completely failed to do so (Figure 1A),
which was similar to what has been found with los-
artan (2). This translated into signiﬁcantly improved
cardiac function in the post-MI animals treated with
candesartan or valsartan, in terms of both ejection
fraction (Figure 1B) and isoproterenol-stimulated
contractility (Figure 1B), whereas irbesartan failed to
halt the cardiac performance decline in these animals
(Figure 1B). Additionally, candesartan signiﬁcantlyreduced post-MI cardiac ﬁbrosis, whereas irbesartan
once again had no effect (data not shown). Finally,
the adverse remodeling-associated biomarkers col-
lagen I, atrial natriuretic peptide, and B-type natri-
uretic peptide were signiﬁcantly reduced by
candesartan or valsartan, whereas irbesartan treat-
ment failed to improve them (data not shown).
Signiﬁcant differences in pharmacological and clin-
ical properties exist among several ARBs currently on
the market (3). Our present study adds another
dimension to these differences: efﬁcacy at adrenal
barr1-dependent post-MI hyperaldosteronism sup-
pression. Our data suggest that candesartan and val-
sartan might be the most preferable members of this
drug class to use in cardiovascular disease, especially if
the condition is complicated by hyperaldosteronism.
In contrast, irbesartan appears to be a weak inhibitor
of barr1-dependent hyperaldosteronism, which might
underlie its lack of beneﬁt in HF with preserved ejec-
tion fraction (3,4), although circulating aldosterone
measurements were not reported in those clinical tri-
als. However, candesartan, unlike irbesartan, seems to
at least reduce hospitalizations in HF with preserved
ejection fraction, and appears to be far superior to los-
artan for HF patients in terms of mortality lowering (3).
On the basis of our present study, the efﬁcacy of each
ARB at suppressing adrenal barr1-dependent aldoste-
rone production might play a role in the observed
clinical differences between the ARBs. This obviously
awaits conﬁrmation from circulating aldosterone
measurements in HF patients treated with these drugs.
Furthermore, the degree to which each ARB sup-
presses adrenal barr1-dependent aldosterone also
might underlie the “aldosterone breakthrough” phe-
nomenon that often hampers the clinical use of ARB
drugs (5). On the basis of our present ﬁndings, it is
quite plausible that the adrenal barr1-dependent
aldosterone production pathway might be involved
in this phenomenon. Thus, the stronger an ARB
(e.g., candesartan, valsartan) is at inhibiting this
pathway, the lower the risk of this side effect.
Candesartan and valsartan are the most efﬁcacious
post-MI hyperaldosteronism suppressors, whereas
irbesartan and losartan are the least efﬁcacious ARBs
in that respect, probably due to different abilities
at blocking adrenal AT1R-activated barr1. These
pre-clinical ﬁndings strongly suggest that the
FIGURE 1 Angiotensin Receptor Blockers and Adrenal barr1-Dependent Post-MI Hyperaldosteronism
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(A) Circulating aldosterone levels in 3-week post-myocardial infarction (MI) rats at 7 days after in vivo adrenal-targeted, adenoviral-mediated
b-arrestin1 (barr1) gene delivery and with simultaneous treatments with vehicle (control) or with: 1) 30 mg/kg body weight/day valsartan; 2) 10
mg/kg body weight/day candesartan; or 3) 40 mg/kg body weight/day irbesartan (all via drinking water). *p < 0.05 versus vehicle or irbesartan
(n ¼ 5 rats/group). (B) Ejection fraction (EF%) and increases in cardiac contractile function (þdP/dtmax) afforded by the drug treatments in
these animals at the end of the 7-day treatments (maximal dose of isoproterenol [Max. Iso]: 333 ng/kg body weight). *p < 0.05 versus vehicle;
†p < 0.05 versus irbesartan (n ¼ 5 rats/group).
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Echocardiographic Area
Strain Diagnostically
Superior to Longitudinal
and Circumferential
Strain?I read with interest and beneﬁt the paper by Smith
et al. (1) detailing 3-dimensional (3D) echocardio-
graphic strain evaluation of the right ventricle for
